Effect of 4-Hexylresorcinol on the Efficiency of Antibiotic Treatment of Experimental Sepsis Caused by Antibiotic-Resistant Klebsiella pneumoniae Strain in Mice

Bull Exp Biol Med. 2021 Aug;171(4):458-460. doi: 10.1007/s10517-021-05249-6. Epub 2021 Sep 20.

Abstract

High efficiency of a combined preparation including synergistic polymyxin B and 4-hexylresorcinol was shown for treatment of experimental sepsis caused by an antibiotic-resistant highly virulent hypermucoid Klebsiella pneumoniae strain KPM9Pmr in mice. Complex therapy with polymyxin B (1 mg/kg) and 4-hexylresorcinol (30 mg/kg) led to cure in 80%; in 20% of these mice, no bacterial cells were found. After treatment with polymyxin B alone, only 50% animals survived and all of them contained bacterial cells. Comparative analysis of the results of monotherapy and combined treatment indicates that 4-hexylresorcinol not only increases the efficiency of antibiotic, but also minimizes persistence of the infection agent and therefore, the risk of development of antibiotic resistance.

Keywords: 4-hexylresorcinol; Klebsiella pneumoniae Pmr; antibiotic resistance; polymyxin; sanified mice.

MeSH terms

  • Animals
  • Animals, Outbred Strains
  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use*
  • Disease Models, Animal
  • Drug Resistance, Multiple, Bacterial / drug effects*
  • Drug Synergism
  • Female
  • Hexylresorcinol / pharmacology*
  • Klebsiella Infections / complications
  • Klebsiella Infections / drug therapy
  • Klebsiella Infections / pathology
  • Klebsiella pneumoniae / drug effects*
  • Klebsiella pneumoniae / pathogenicity
  • Mice
  • Microbial Sensitivity Tests
  • Polymyxin B / pharmacology
  • Polymyxin B / therapeutic use
  • Polymyxins / analogs & derivatives
  • Polymyxins / pharmacology
  • Polymyxins / therapeutic use
  • Sepsis / drug therapy*
  • Sepsis / microbiology

Substances

  • Anti-Bacterial Agents
  • Polymyxins
  • polymyxin B(1)
  • Polymyxin B
  • Hexylresorcinol